HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

This item is licensed under: Creative Commons Attribution 3.0 Unported

Files in This Item:
78_ModRheumatol21_343.pdf221.59 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/62836

Title: Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Authors: Koike, Takao Browse this author →KAKEN DB
Harigai, Masayoshi Browse this author →KAKEN DB
Inokuma, Shigeko Browse this author
Ishiguro, Naoki Browse this author →KAKEN DB
Ryu, Junnosuke Browse this author →KAKEN DB
Takeuchi, Tsutomu Browse this author →KAKEN DB
Tanaka, Yoshiya Browse this author →KAKEN DB
Yamanaka, Hisashi Browse this author →KAKEN DB
Fujii, Koichi Browse this author
Yoshinaga, Takunari Browse this author
Freundlich, Bruce Browse this author
Suzukawa, Michio Browse this author
Keywords: DAS28
Etanercept
Postmarketing surveillance study
Rheumatoid arthritis
Issue Date: 2011
Publisher: Springer
Journal Title: Modern Rheumatology
Volume: 21
Issue: 4
Start Page: 343
End Page: 351
Publisher DOI: 10.1007/s10165-010-0406-3
Abstract: Our aim was to evaluate real-world safety and effectiveness in a 6-month postmarketing surveillance study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected. Adverse events (AEs) and serious adverse events (SAEs) were reported in 4336 (31.2%) and 857 (6.2%) patients, respectively. The most frequent AEs were injection site reactions (n = 610, 4.4%) and rash (n = 339, 2.4%), whereas pneumonia (n = 116, 0.8%) and interstitial lung disease (n = 77, 0.6%) were the most frequent SAEs. Significant improvement in the proportion of patients with a good European League Against Rheumatism (EULAR) response was observed from week 4 (17.6%) to week 24 (31.6%) (p < 0.001); 84.3% of patients had good or moderate EULAR responses at week 24. The percentage of patients achieving remission increased significantly from week 4 (9.3%) to week 24 (18.9%) (p < 0.001). Patients with early moderate RA were less likely to experience SAEs and were more likely to achieve remission compared with patients with more severe disease. The safety and effectiveness of etanercept was demonstrated in Japanese patients in one of the largest observational trials conducted thus far in RA patients treated with biologics.
Rights: https://creativecommons.org/licenses/by/3.0/
Type: article
URI: http://hdl.handle.net/2115/62836
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 小池 隆夫

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University